528283

Polo-like Kinase Inhibitor II, BTO-1

The Polo-like Kinase Inhibitor II, BTO-1, also referenced under CAS 40647-02-7, controls the biological activity of Polo-like Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• 同義詞: Polo-like Kinase Inhibitor II, BTO-1, 5-Cyano-7-nitro-2-(benzothiazolo-N-oxide)-carboxamide
• 經驗公式（希爾表示法）: C₉H₄N₄O₄S
• CAS號碼: 40647-02-7
• 分子量：: 264.22
• MDL號碼: MFCD11045282
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 品質等級: 100
• 化驗: ≥97% (HPLC)
• 形狀: solid
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; protect from light
• 顏色: beige to brown
• 溶解度: DMSO: 1 mg/mL
• 運輸包裝: ambient
• 儲存溫度: 2-8°C
• InChI: 1S/C9H4N4O4S/c10-3-4-1-5-7(6(2-4)13(16)17)18-9(8(11)14)12(5)15/h1-2H,(H2,11,14)
• InChI 密鑰: FKRBAXZAJBBIAJ-UHFFFAOYSA-N

描述

一般說明

A cell-permeable benzothiazolo-N-oxide compound that targets the ATP-binding pocket of polo-like kinase and is shown to inhibit Plk1 kinase activity in cell-free kinase assays (IC₅₀ = 8.0 µM) and suppress the phosphorylation of cellular Plk1 substrate Cdc25C in rat kangaroo kidney-derived PTK cells (75% inhibition at 6.3 µM). BTO-1 treatment of cultured cells results in mitosis defects consistent with loss-of-Plk1 phenotypes seen in Plk1 RNAi-treated U20S cells, including the appearance of monopolar spindles and the reduction of γ-tubulin at the centrosomes. Plk1 inhibition by BTO-1 in HeLa cells results in a blockage of Rho and Rho-GEF recruitment, which is essential for the assembly of a functional contractile ring.

包裝

Packaged under inert gas

警告

Toxicity: Harmful (C)

重構

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

其他說明

Brennan, I.M., et al. 2007. PloS ONE2, e409.
Peters, U., et al. 2006. Nat. Chem. Biol.2, 618.
McInnes, C., et al. 2006. Nat. Chem. Biol.2, 608.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3